Kura Oncology, Inc. (NASDAQ:KURA – Free Report) – Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Kura Oncology in a research report issued on Tuesday, March 4th. Cantor Fitzgerald analyst L. Watsek expects that the company will post earnings of ($2.94) per share for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.
Several other research analysts also recently weighed in on the company. Jefferies Financial Group lowered their target price on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, November 21st. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of Kura Oncology in a report on Thursday, February 27th. Scotiabank dropped their target price on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. TD Cowen reissued a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $28.00 price objective on shares of Kura Oncology in a report on Thursday, February 6th. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $25.50.
Get Our Latest Stock Analysis on KURA
Kura Oncology Stock Performance
NASDAQ KURA opened at $7.70 on Thursday. The firm has a market cap of $598.78 million, a P/E ratio of -3.26 and a beta of 0.85. Kura Oncology has a 52-week low of $6.98 and a 52-week high of $24.17. The business’s 50-day moving average price is $8.04 and its 200 day moving average price is $13.51. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.
Kura Oncology (NASDAQ:KURA – Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million.
Hedge Funds Weigh In On Kura Oncology
Several large investors have recently added to or reduced their stakes in KURA. China Universal Asset Management Co. Ltd. increased its position in Kura Oncology by 11.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock worth $144,000 after purchasing an additional 1,750 shares during the last quarter. Rhumbline Advisers boosted its holdings in Kura Oncology by 2.0% in the fourth quarter. Rhumbline Advisers now owns 99,991 shares of the company’s stock valued at $871,000 after acquiring an additional 1,923 shares during the last quarter. Harbor Capital Advisors Inc. lifted its stake in shares of Kura Oncology by 4.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock valued at $430,000 after purchasing an additional 2,076 shares in the last quarter. Teacher Retirement System of Texas lifted its holdings in shares of Kura Oncology by 19.9% during the 4th quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company’s stock valued at $120,000 after acquiring an additional 2,285 shares in the last quarter. Finally, MetLife Investment Management LLC boosted its position in Kura Oncology by 6.6% during the 4th quarter. MetLife Investment Management LLC now owns 44,828 shares of the company’s stock worth $390,000 after purchasing an additional 2,776 shares during the period.
Insider Transactions at Kura Oncology
In related news, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. The trade was a 5.32 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock valued at $92,307 in the last 90 days. 5.50% of the stock is currently owned by insiders.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
See Also
Receive News & Ratings for Kura Oncology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Kura Oncology and related companies with MarketBeat.com’s FREE daily email newsletter.
